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Since 2000, the Defense and Veterans Brain Injury Center has reported on 383,947 service members with medically diagnosed traumatic brain injuries, the great majority classified with mild traumatic brain injury (mTBI, or concussion) (1) . The prevalence of mTBI among service members returning from Operation Enduring Freedom or Operation Iraqi Freedom has been estimated to range from 8% to 23% (2-9), depending on the time frame of service and the intensity of combat operations.
While most military and civilian TBI (traumatic brain injury) is classified as mild (1, 10) , there is uncertainty about the persistence and trajectory of postconcussive symptoms (PCS), particularly for deployment-related injuries. A 2014 systematic review by Cassidy et al. (11) of high-quality prognostic studies of symptom recovery in mTBI civilian populations concluded that most patients recover within 3 months to a year, although the authors highlighted the need for additional high-quality research. Likewise, there is controversy about the extent to which deploymentrelated mTBI leads to persistent PCS, with some cross-sectional studies suggesting that persistent problematic symptoms are more frequent than in civilian populations and that psychological comorbidities are an important determinant (2, 4) . In another cross-sectional study it was reported that posttraumatic stress disorder (PTSD) and mTBI were each independently associated with persistent symptoms, and a combination of the 2 conditions was more strongly associated with prevalent symptoms than either condition alone (12) . The concurrent review of the evidence on symptomatology after military mTBI conducted by the same international panel as Cassidy et al. found only limited high-quality prognostic evidence and no prospective longitudinal studies that could provide evidence on recovery over time in military subjects (13) . Several longitudinal studies of military subjects returning from Operation Iraqi Freedom and/ or Operation Enduring Freedom have been published since this review (8, 9, 14, 15) . These recent prognostic studies, using different symptom measures and study populations, suggest that military mTBI is associated with persistent PCS (independent of psychological comorbidities), and with more symptomatology than is typically found in civilian mTBI.
In our previous work (9) we found that soldiers with deployment mTBI were twice as likely as others to report severe or very severe PCS 3 months after deployment. The aim of the present study was to further characterize the prevalence, prognosis, and symptom trajectories in this cohort and to extend follow-up to 1 year after deployment. In our first analysis we noted a surprisingly high prevalence of PCS in the soldiers without a recent mTBI, presumably due to other factors or comorbidities related to the deployed environment. We were therefore also interested in whether longer-term symptom recovery patterns were the same in the soldiers with and without a reported deployment-related mTBI.
METHODS

Study population and recruitment
The design of the Warrior Strong study has been described in detail (9) and is registered at ClinicalTrials.gov (NCT01847040). Briefly, soldiers were recruited during routine postdeployment health assessments at 2 large US Army bases (Fort Carson and Fort Bragg) within a few days of their return from deployment to Iraq or Afghanistan. Soldiers who had sustained 1 or more mTBIs during the previous deployment were identified using the Brief Traumatic Brain Injury Screen (16) . A positive mTBI screening was defined if soldiers endorsed both of the following: 1) exposure to an injury event in theater that 2) resulted "immediately" in an alteration of consciousness, loss of consciousness, or not remembering the injury. Once potential study participants completed the TBI screening, usually in groups of 50-100, 2 randomization algorithms (one for TBI-screened-positive service members and one for TBI-screened-negative service members) were used to determine which service members were invited to participate in the study. Screened-positive soldiers were oversampled. The invitations and consents were performed by nonuniformed staff.
Inclusion criteria were 1) completed the TBI screen, 2) recently returned from Iraq or Afghanistan, 3) agreed to participate, 4), provided informed consent, and 5) had not been medically evacuated from theater. We excluded 2 soldiers who were later determined to have likely sustained more than a mild TBI. Followup data were collected approximately 3, 6, and 12 months after baseline, in person or by telephone. The institutional review boards of Fort Carson, Colorado, and Fort Bragg, North Carolina, provided primary study oversight.
Measures
In addition to evaluating participants, we collected 1) demographic information, including race/ethnicity (black, white, Hispanic, other/multiple), age, sex, and education (high school/ General Educational Development certificate, some college, college graduate or higher); and 2) military service characteristics, including rank (E1-E9 and chief warrant officer/ officer), combat military occupational specialty, and number of deployments.
The Ohio State University TBI Identification Method is a structured clinical interview designed to elicit self-reports of lifetime history of TBI and has been found in previous research to have acceptable levels of reliability and validity in the civilian population (17) . In our study the clinical interviewer was blind to the results of the screening questionnaire. We used the Ohio State University TBI Identification Method to calculate the number of lifetime TBI injuries.
Participants completed a comprehensive battery of measurements at baseline and each follow-up visit, including the Neurobehavioral Symptom Inventory (NSI) (18) . The NSI is a 22-item self-report inventory of symptoms commonly associated with, although not specific to, concussion. The NSI is frequently used by the Department of Defense and Veterans Affairs, and has been recommended as an outcome measure of TBI research (19) . Participants rate the presence and severity of each symptom within the previous 2 weeks on a 5-item Likert scale (range, 0-4, with higher scores indicating greater symptom severity). The Validity-10 scale (20) , which measures possible symptom exaggeration for this instrument, identified 11 participants (8 who screened positive for mTBI and 3 who screened negative), and these were excluded from further analyses. The PTSD Checklist-Civilian Version (PCL-C) is a standardized self-report scale for PTSD that includes 17 items corresponding to key symptoms of PTSD and yields a summary score of 17-85. The PCL score was used as a self-report measure of PTSD symptom severity in our main analysis (21, 22) .
Statistical methods
Analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina), and Stata, version 13 (StataCorp LLC, College Station, Texas). Descriptive statistics were presented as means or percentages for continuous and categorical variables, respectively. Baseline differences in participant characteristics were assessed using t tests or χ 2 tests as appropriate. We used a P value of 0.05 for statistical significance.
Longitudinal analysis
Our primary outcome was reporting 1 or more "severe" (rating = 3) and/or "very severe" (rating = 4) symptoms on the NSI. This threshold was selected because at this level the symptoms were described as impairing daily functioning, which we considered to have potential clinical relevance. Our primary exposure was mTBI sustained during the most recent deployment. Repeated measures models were used to assess change over time in this dichotomous outcome using PROC GEN-MOD (SAS) with a binary distribution, a log link, and a compound symmetry correlation matrix. Estimates represented the predicted relative risk for having a severe and/or very severe NSI symptom for those with mTBI compared with those without mTBI at baseline and at each subsequent study evaluation.
In order to determine whether the relationship between mTBI exposure and NSI symptoms was constant over time, repeated measures models with time, mTBI status, and an interaction variable of mTBI status × time were first fitted without adjustment. Because the interaction of mTBI status × time was not statistically significant (β = −0.002; z score = −0.36; P = 0.72), it was removed from all subsequent models. Subsequent models adjusted individually for covariates of interest, including site, race/ethnicity, sex, education, pay grade, and combat military occupational specialty. Interactions × time for each covariate were assessed. Only significant interactions or those significantly affecting the association between mTBI status and NSI score were included in final models (difference tested with a χ 2 test). Forward stepwise regression techniques were used wherein covariates that were significant when individually added were included in the final model. The final model included the main effects: mTBI status, time, site, race/ ethnicity, sex, pay grade, and total baseline PTSD ChecklistCivilian Version score. No 2-way interactions × time or 3-way interactions were statistically significant, and they were thus not included in the final model.
Finally, proc GENMOD (SAS) with a negative binomial distribution was used to determine the association of mTBI status at each time point with each of the 4 most prevalent baseline symptoms (sleep, irritability, forgetfulness, and headache).The same modeling strategies were used for this step. There was no significant interaction between mTBI status and time for sleep, irritability, or forgetfulness, so the interaction term was removed from those final models. The interaction between mTBI status and time was significant for headache and was thus reported. Pooled results for the 2 study sites are presented because no significant interaction between mTBI screening status and study site was observed.
RESULTS
Of the 17,850 soldiers returning to Fort Carson who completed the mTBI screen, 9.5% screened positive for probable mTBI. Of the 6,824 screened soldiers returning to Fort Bragg, 7.9% screened positive for probable mTBI. A total of 1,567 participants made up the baseline sample, of whom 965 (62%) completed the 3-month follow-up, 754 (48%) completed the 6-month follow-up, and 632 (40%) completed the 12-month follow-up. Three hundred eighty-eight (25%) participants were present for all 4 time periods (252 mTBI-negative; 136 mTBI-positive). Table 1 displays the descriptive characteristics of the total baseline sample (n = 1,567).The mean age at baseline was 27.0 (standard deviation, 6.0) years (range, 19-51). The cohort consisted of 1,447 men (92%) and 120 women (8.0%). No statistically significant (P < 0.05) differences existed between the mTBI-screened-positive and mTBI-screened-negative groups according to age, sex, or number of deployments. Service members who screened positive for mTBI were more often from the Fort Carson study site (325; 58%), whereas service members who screened negative for mTBI were more often from the Fort Bragg study site (596; 59%). Service members who screened positive for mTBI differed according to race, educational level, and rank. As expected, those with mTBI were more likely to report a blast exposure and have a combat military occupational specialty. Most participants (67% of those who screened positive for mTBI and 57% those who screened negative; P < 0.001) reported having 1 or more mTBIs before the most recent deployment.
The analytical sample for the longitudinal analysis included those participants with a baseline NSI score who had at least 1 follow-up evaluation (1,162/1,567, 74%). A nonrespondent analysis (Web Tables 1 and 2 , available at https://academic.oup.com/ aje) did not find important demographic differences in the analytical sample compared with the baseline sample. The heat map (Figure 1 ) presents the prevalence of severe and/or very severe symptoms at the baseline, 3-month, 6-month, and 12-month interviews for each of the 22 symptoms and overall. Those with mTBI ( Figure 1B) were more than twice as likely to report one or more symptoms at baseline compared with those without mTBI ( Figure 1A ) (47% vs. 21%, χ 2 = 84.23, P < 0.0001). This pattern was also observed at each subsequent follow-up visit: month 3 (49% vs. 26%, χ 2 = 49.27, P < 0.0001), month 6 (53% vs. 31%, χ 2 = 34.99, P < 0.0001), and month 12 (54% vs. 28%, χ 2 = 40.37, P < 0.0001). The 4 most commonly reported symptoms at baseline for both those with and those without mTBI were sleep problems, irritability, forgetfulness, and headaches ( Figure 1) .
The risk of having 1 or more severe and/or very severe NSI symptoms at baseline was greater among those with mTBI, compared with those without mTBI (relative risk (RR) = 1.94, 95% confidence interval (CI): 1.71, 2.19; Table 2 ). This relationship was constant over 12 months (β = −0.002, z score = −0.36, P = 0.72) and remained significant after adjustment for site, race/ethnicity, sex, education, pay grade, and combat military occupational specialty in a model that adjusted for all significant covariates, including baseline PTSD (Table 3 ). In this model, symptoms were less prevalent in the Fort Bragg group compared with the Fort Carson group (Table 3: adjusted RR = 0.59, 95% CI: 0.46, 0.76) but were otherwise similar according to sex, race, and military rank. The relative risk of severe and/or very severe NSI symptoms associated with mTBI was attenuated from 1.71 in a model without PTSD to 1.34 in a model with PTSD and retained significance.
When looking at the 4 most common symptoms, the risk of having a severe and/or very severe sleep score at all time points was greater among those with mTBI than among those without (RR = 2.19, 95% CI: 1.83, 2.62, Table 2 ). The risk of having a severe and/or very severe forgetfulness score at all time points was greater among those with mTBI than among those without (RR = 2.56, 95% CI: 2.03, 3.23, Table 2 ). The risk of having a severe and/or very severe irritability score at all time points was greater among those with mTBI than among those without (RR = 2.73, 95% CI: 2.10, 3.42, Table 2 ).
The pattern for headache was somewhat different from that for the other common symptoms. Headache showed the largest prevalence difference between those with and without mTBI at baseline (RR = 3.44, 95% CI: 2.41, 4.92) and continued to do so at the 12-month follow-up interview (RR = 3.26, 95% CI: 2.32, 4.56), although there was a significant interaction × time (RR = 0.96, 95% CI: 0.92, 0.99). This decrease (from RR = 3.44 to RR = 3.26) was due to an increased prevalence of headache in those without mTBI, while the prevalence of headache in those with mTBI remained stable (data not shown).
DISCUSSION
We evaluated the presence and trajectory of a broad inventory of symptoms commonly associated with, but not specific to, concussion in a large cohort of US soldiers returning (but not medically evacuated) from deployment to Afghanistan or Iraq. Symptoms were assessed at the time of postdeployment health assessments and again at 3, 6, and 12 months. The soldiers with a history of a recent-deployment mTBI were approximately twice as likely as others to endorse severe and/or very severe symptoms at baseline and at each subsequent follow-up visit. Sleep disturbances, irritability, forgetfulness, and headache were the most commonly endorsed symptoms for the participants with deployment mTBI history at most time points. These results extend our earlier findings to 1 year of follow-up and suggest that these symptoms, whether or not associated with concussion, do not diminish over this time period.
Three other recent longitudinal studies measured symptom prevalence in military personnel with and without mTBI (summarized in Table 4 ) (8, 14, 15) . While these other studies and the present study differ in outcomes assessed, study population (clinical vs. nonclinical), time since injury, and assessment of mTBI, all reported persistent symptomatology among soldiers with deployment mTBI. The present study shares the most design features with the large study by Stein et al. (8), but we included an additional follow-up period (12 months vs. 9 months), checked the validity of symptom self-reports with the Validity-10 scale, used blinded clinical evaluations to assess the validity of selfreported mTBI, and reported details on specific symptoms. Findings were, however, similar, with Stein et al. (8) also estimating higher odds of symptoms at both 3 months after deployment (aRR = 2.88, 95% CI: 1.65, 5.05) and 6 months relative to baseline (aRR = 2.92, 95% CI: 1.82, 4.68) for mTBI.
Strengths of our study include our randomly selected cohort of recently deployed soldiers who were evaluated outside of a clinical context and who had not necessarily sought medical care for their injuries or symptoms. We used a rigorous design to follow the same individuals for 1 year with up to 3 follow-up assessments. Our cohort of active-duty soldiers was fit for duty at the time of deployment, so important comorbidities such as alcoholism, mental health issues, and other physical symptoms were not present to a degree that would have precluded deployment. Nonetheless, there are several limitations that should be acknowledged and considered when interpreting our study results. By necessity, our study relied on self-reporting of symptomatology, although the NSI has been validated in prior studies (23, 24) . While loss to follow-up occurred during the 1-year postdeployment period, we note that our nonrespondent analysis did not identify important differences between participants and nonparticipants based on baseline characteristics, including PTSD. Because this was a sample of military personnel returning from 2 combat arenas (i.e., Iraq and Afghanistan), the generalizability of the study to other military populations or locations may be limited. We did not attempt to parse out the complex and potentially reciprocating influences of combat-related comorbidities with mTBI over the 1-year recovery period studied in these soldiers.
It is hoped that the reliable biomarkers, including imaging biomarkers, will be identified to help disentangle the respective roles played by the various contributory and highly correlated factors related to poor symptom recovery (10, 25) . Given the recent findings of larger than expected co-occurring posttraumatic stress symptoms even in civilian mTBI patients (26) , these issues remain an important area for future investigation in both military and civilian populations. Prior studies have reported inconsistent findings about the relationship between PTSD and postconcussive (e.g., NSI) symptoms; some studies have suggested that the continued symptomatology related to deployment mTBI of most symptoms is largely due to comorbid PTSD (2, 4) . Others have reported that both mTBI and PTSD contribute to continued symptomatology (8, 12) . In the present study, the Frequencies of any symptom for those without mTBI at baseline, 3, 6, and 12 months were 21%, 26%, 31%, and 28%, respectively; for those with mTBI, at baseline, 3, 6, and 12 months, they were 47%, 49%, 53%, and 54%, respectively. majority of participants with mTBI (85%) did not reach the threshold for positive PTSD at baseline; however, many continued to experience elevated levels of severe symptomatology compared with those without mTBI. Some have argued that the persistent mTBI-related sequelae may be better explained by the presence of PTSD symptoms. We note that mTBI was still significantly associated with a higher risk of severe and/or very severe symptoms even after controlling for the PTSD symptom score, although the effect of mTBI was attenuated. This finding should be interpreted with caution because the PTSD and NSI symptom inventories are highly correlated, which complicates the interpretation of models in which both symptom inventories are included.
The extent to which persistent symptoms lead to difficulties in performing some military specialties or contributing effectively in other roles is a question for future studies. Certainly, future treatment studies are warranted to investigate whether chronic symptoms and problems in these military populations can be ameliorated. It should be noted that mTBI does not usually result in medical discharge in military populations (27, 28) . Moreover, clinicians are encouraged to treat symptoms with existing evidencebased treatments as outlined in the Veterans Affairs/Department of Defense Clinical Practice Guidelines for the Management of Concussion/Mild TBI (29) . In particular, both groups reported sleep-related difficulties, which may be contributing to other symptoms (e.g., forgetfulness and headache) (30) . As such, consideration is indicated as to whether addressing sleep problems should be a primary focus for intervention.
In summary, the findings reported here suggest that severe and/or very severe PCS remain highly prevalent at 1-year follow-up for service members with deployment-related mTBI. These results are similar to those of several other recent longitudinal studies of service members returning from combat service, despite diverse research methodologies. Several thoughtful reviews of the state of the science of mTBI/TBI (10, (31) (32) (33) have restated the importance of mTBI as a public health issue, and that this complex and highly prevalent injury requires new conceptualizations, additional research, and rethinking about medical evaluation and treatment. Future longitudinal studies, with longer follow-up periods, of outcomes of service members after deployment-related mild TBI would improve our understanding of the dynamic relationship between sustained mild TBI and persistent PCS as well as fill a major gap regarding the risk factors for postdeployment PCS. Health systems may consider targeting some of the more highly prevalent and highly elevated symptom burdens over time in formats readily accessible to this population. Studies focused on development of effective treatments are clearly needed.
